Drugs that contain Osimertinib Mesylate

1. List of Tagrisso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9732058 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(9 years from now)

US11524951 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(9 years from now)

US8946235 ASTRAZENECA 2-(2,4,5-substituted-anilino) pyrimidine compounds
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183020 ASTRAZENECA Pharmaceutical compositions comprising AZD9291
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 18, 2027
New Indication (I) Dec 18, 2023

Market Authorisation Date: 13 November, 2015

Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; Treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; Adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations

Dosage: TABLET;ORAL

How can I launch a generic of TAGRISSO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in